

PAR/CS/NSE/2021-22/47

Date: 09/11/2021

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra


Subject: Outcome of the Board Meeting held on Tuesday, 9th day of November, 2021 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on **Tuesday, 9th day of November, 2021 at 4:00 PM at 333/1, G.I.D.C. Industrial Estate, Phase-II, Chitra, Bhavnagar – 364004** to transact the following business:

Item No.	Outcomes
1.	After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record the Unaudited Standalone Financial Results of the Company for the quarter and half year ended on 30 th September, 2021 along with Limited Review Report given by CA Vipul V. Dhamsania, Partner of V Dhamsania & Associates, Chartered Accountants having valid Peer Review Certificate, Statutory Auditor of the Company. (Limited Review Report is attached as Annexure)
2.	The Board considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter and half year ended on 30 th September, 2021 The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay.
3.	The Board has declared an Interim Dividend for the Financial Year 2021-22 on Equity Share at the rate of 12.50 % i.e ₹.1.25 per Equity share of the face value of ₹. 10 each to the Equity Shareholders of the Company



4.	The Board has decided 23rd day of November, 2021 as Record Date for the purpose of Interim Dividend. The Interim Dividend shall be paid to the Equity shareholders of the Company whose name appear on the Register of Members of the Company or in the records of the respective Depositories as beneficial owners of the shares as on 23rd day of November, 2021 , which is the record date fixed for the purpose, And payment shall be maid within 30 days of the from the date of the this Board Meeting by complying Companies Act, 2013 & rules made thereto.*
5.	The Board has approved opening of Interim Dividend account of Par Drugs and chemicals Limited with Kotak Mahindra Bank Limited in terms of the agenda item no. 3
6.	The Board took note of Investor grievances report for the quarter ended 30 th September, 2021
With the permission of the Chairman of the Company, following other matter were considered	
7.	The Board has approved the proposal of purchase of motor vehicle named Kia Carnival Limousine Plus 7 STR for an amount of approx. Rs. 38.00 Lakh in the name of Par Drugs And Chemicals Limited for the use by Mr. Falgun V. Savani ,Managing Director of the Company as per the agreement made between MD and the Company during at the time of appointment
8.	The Board has approved the term insurance plan as being decided on negotiation by the Company with the insurance provider company(ies) for its key men i.e. MD, Whole time Director and Ceo of the company for the financial year 2021-22 that should be endowed in favour of the company & the amount should be received by the company in case of the maturity and authorized any of the present director of the Company to do sign/digitally sign all such necessary forms, documents, papers, and to do all such acts, matters, deeds as may be required from time to time.

*Further, in continuation of our intimation dated 27th September, 2021 & 26th October, 2021 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company was closed w.e.f. 30th September, 2021 and **shall remain closed upto completion of 48 hours of record date** for the purpose of interim dividend for Designated persons, Designated employees and their Immediate relatives.

The Board Meeting was commenced at 4:00 PM and concluded at 5:32 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED


(Falgun V. Savani)
Managing Director
DIN: 00198236




Epcl: Limited Review Report with Financial Statements

PAR DRUGS AND CHEMICALS LIMITED

NOTES:

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and half yearly financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 9th November, 2021
3. The Statutory auditors of the company have carried out Limited Review of the above quarterly and half yearly financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS.
5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures.
6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
7. The Company does not have any subsidiary, associates or joint venture as on 30th September, 2021; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.



8. The above unaudited financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.

9. The Status of investors complaints are as follows:

I. Pending at the beginning of the quarter	-	0
II. Received during the quarter	-	0
III. Disposed-off during the quarter	-	0
IV. Remaining unresolved at the end of the quarter	-	0

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited



Falgun V Savani
(Chairman & Managing Director)
(DIN - 00198236)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited



Jigneshbhai V Savani
(Director & CEO)
(DIN - 00198203)



Bhavnagar, 9th November, 2021